There have been many previously reported cases of adult-onset Still's disease (AOSD)
which were successfully treated with tocilizumab (TCZ). However, the efficacy and safety of …

Adult-onset Still's disease (AoSD) is a rare but clinically well-known, polygenic, systemic
autoinflammatory disease. Owing to its sporadic appearance in all adult age groups with …

We conducted a retrospective observational study to describe a cohort and identify the
prognostic factors in adult-onset Still disease (AOSD). Patients enrolled in this retrospective …

Adult-onset Still's disease (AOSD) poses a not well estimated burden on patients and
healthcare systems. To assess this burden, a systematic review (SR) was undertaken to …

Background/objectives Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset
Still's disease (AOSD) mostly derive from small case series. Herein we report a registry …

Over the last 20 years, classification criteria have been developed for rheumatic diseases (1,
7). Many of these diseases do not have unequivocal or pathognomonic features …

Adult-onset Still's disease (AOSD) is a polygenic systemic autoinflammatory disease which
is associated with increased morbidity and mortality. Pulmonary involvement is a rare, but …

Objectives To evaluate the impact of obesity in patients with adult-onset Still's disease
(AOSD) and to assess their clinical characteristics and disease outcomes. Methods The …

Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal
antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset …

ABSTRACT Introduction: Adult-onset Still's disease (AOSD) is a rare multisystem
autoinflammatory disorder of unknown etiology, with clinical and biological similarities with …